enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 1. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hovedkontor
- SAINT-LAURENT, Canada
- Administrerende direktør
- Mr. Ronald H. W. Cooper
- Ansatte
- 81
- Udestående aktier
- 67.02 mio. pr. 2026-09-02
- Free float
- 32.75 mio.
- Markedsværdi
- 132.02 mio. USD
- Insidere
- 0.11%
- Institutionelle investorer
- 84.11%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
Beskrivelse
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Børser og tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.8 -3.74% | almindelige aktier |
Udbytte
Ingen udbyttebetalinger fundet (tjekket 07.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mio. | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mio. | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mio. | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mio. | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mio. | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mio. | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mio. | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mio. | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mio. | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mio. | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
